Securitization of Royalty Payments from Investments by a Private Fund
Paul Capital Partners
Chadbourne represented Paul Capital Partners in a $229 million securitization of pharmaceutical royalty payments. Payments are from a portfolio of 23 biopharmaceutical products, medical devices and diagnostics selected from 13 of the 19 investments made by Paul Royalty Fund, L.P. The transaction was supported by a financial guaranty policy issued by Ambac Assurance Corporation and funded by ABCP conduits.